Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

CAR-T cell therapy has revolutionized the treatment of relapsed and refractory B-acute lymphoblastic leukemia (B-ALL), with ...

Discover how the ALA-CART platform enhances CAR T cell efficacy against antigen-low leukemias. With improved LAT activation, ...

During a live event, John L. Wagner, MD, moderated a discussion on when to refer patients for CAR T-cell therapy and what ...

In an interview with Arthur Stril, chief business officer and interim CFO at Cellectis, we explore how gene editing and ...

Scientists have supercharged CAR-T therapy, making it more powerful against elusive cancer cells that usually escape ...

Researchers have successfully developed a supercharged iteration of CAR-T cell therapy that can enhance the effectiveness and longevity of the cells, particularly against cancer cells that are harder ...

In a real-world study, researchers found this data by comparing treatment patterns, healthcare resource utilization, and ...

India's gene therapy for blood cancers shows 73% response rate, offering hope and cost-effective treatment for patients.

A “complete eradication” of B cells with chimeric antigen receptor T-cell therapy is responsible for the long-term, drug-free ...

Researchers at the University of Colorado Anschutz Medical Campus have successfully developed a supercharged iteration of CAR ...

CAR-T cell therapy involves extracting a patient’s T-cells, modifying them to recognize cancer cells, and then reinfusing them into the patient where they target cancer cells throughout the body.